EyePoint Pharmaceuticals (EYPT) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading.
The company said the trial demonstrated "clinically meaningful outcomes," such as continued safety with no Duravyu-related ocular or systemic serious adverse events, and an early and sustained improvement in vision and anatomical control.
EyePoint shares were 23% lower in premarket trading
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。